RhumbLine Advisers
INZY

RhumbLine Advisers’s Inozyme Pharma INZY Stock Holding History

RhumbLine Advisers’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-72,459
Closed -$65.9K – 4197
2025
Q1 		$65.9K Sell
72,459
-4,792
-6% -$6.64K ﹤0.01% 3505
2024
Q4 		$214K Buy
77,251
+434
+0.6% +$1.65K ﹤0.01% 3159
2024
Q3 		$402K Sell
76,817
-187
-0.2% -$971 ﹤0.01% 2853
2024
Q2 		$343K Buy
77,004
+13,867
+22% +$67.2K ﹤0.01% 2923
2024
Q1 		$484K Buy
63,137
+2,843
+5% +$15.6K ﹤0.01% 2686
2023
Q4 		$257K Buy
60,294
+14,365
+31% +$51K ﹤0.01% 3057
2023
Q3 		$193K Buy
45,929
+2,518
+6% +$12.8K ﹤0.01% 3176
2023
Q2 		$242K Buy
+43,411
New +$257K ﹤0.01% 3139
2022
Q2 		– Sell
-12,890
Closed -$53K – 3167
2022
Q1 		$53K Sell
12,890
-174
-1% -$1.02K ﹤0.01% 2968
2021
Q4 		$89K Sell
13,064
-398
-3% -$3.44K ﹤0.01% 2952
2021
Q3 		$156K Buy
13,462
+675
+5% +$10.5K ﹤0.01% 2945
2021
Q2 		$218K Buy
+12,787
New +$222K ﹤0.01% 2902

Other funds holding INZY

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

RhumbLine Advisers's INZY Position: Q2 2025 in Review

RhumbLine Advisers sold out of Inozyme Pharma (INZY) in Q2 2025, closing a stake of 72,459 shares — an estimated $65.9K sold.

RhumbLine Advisers first reported a position in INZY in Q2 2021 and held it in 12 quarters. The position peaked at $484K in Q1 2024. 86 funds tracked by Wall St. Rank hold INZY as of Q2 2025.

  • RhumbLine Advisers reported no remaining Inozyme Pharma position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 72,459 Inozyme Pharma shares in Q2 2025, an estimated $65.9K.
  • RhumbLine Advisers first reported a position in Inozyme Pharma in Q2 2021 and held it in 12 quarters.
  • RhumbLine Advisers's Inozyme Pharma position peaked at $484K in Q1 2024.
  • 86 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.